Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Egalet a/s |
---|---|
Information provided by: | Egalet a/s |
ClinicalTrials.gov Identifier: | NCT00446069 |
The purpose of the study is to determine the effect of Egalet® Morphine once daily compared to MST Continus twice daily on pain intensity and use of rescue medication for break through pain after 2 weeks of treatment in patients with pain due to cancer.
Condition | Intervention | Phase |
---|---|---|
Pain Cancer |
Drug: Morphine Sulphate |
Phase II |
Study Type: | Interventional |
Study Design: | Supportive Care, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Active Control, Crossover Assignment, Safety/Efficacy Study |
Official Title: | A Double-Blind, Randomized, 2-Way Cross-Over, Phase II, Efficacy Trial in Cancer Patients to Assess the Overall Efficacy, Patient Preference, Morphine Related Side Effect Profile and Safety of the Egalet® Controlled Release Morphine Formulation 30-240 mg Once Daily Compared to MST Continus® 15-120 mg Twice Daily After 2 Weeks of Treatment |
Enrollment: | 36 |
Study Start Date: | August 2007 |
Study Completion Date: | August 2008 |
Primary Completion Date: | June 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Egalet® morphine: Experimental |
Drug: Morphine Sulphate
Egalet® morphine, Controlled Release 30 mg Oral tablet once daily for 2 weeks and MST Continus® 15 mg twice daily for 2 weeks
|
MST Continus®: Active Comparator |
Drug: Morphine Sulphate
Egalet® morphine, Controlled Release 30 mg Oral tablet once daily for 2 weeks and MST Continus® 15 mg twice daily for 2 weeks
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Lithuania | |
Site 50 | |
Vilnius, Lithuania | |
Site 51 | |
Kaunas, Lithuania | |
Poland | |
Site 60 | |
Bydgoszcz, Poland | |
Site 61 | |
Warszawa, Poland | |
Site 65 | |
Włocławek, Poland | |
Site 63 | |
Bielsko-Biaia, Poland | |
Site 64 | |
Wrocław, Poland | |
Site 62 | |
Poznań, Poland |
Study Director: | Christine Andersen, MSc Pharm | Egalet a/s |
Responsible Party: | Egalet ( Lillian Jespersen, CRA/Medical Writer ) |
Study ID Numbers: | MP-EG-002, EudraCT number: 2006-006579-19 |
Study First Received: | March 9, 2007 |
Last Updated: | September 3, 2008 |
ClinicalTrials.gov Identifier: | NCT00446069 |
Health Authority: | Lithuania: State Medicine Control Agency - Ministry of Health |
Morphine Pain |
Sensory System Agents Therapeutic Uses Physiological Effects of Drugs Central Nervous System Depressants Narcotics |
Peripheral Nervous System Agents Analgesics Central Nervous System Agents Pharmacologic Actions Analgesics, Opioid |